Cmv reactivations in allogeneic hematopoietic stem cell transplant from hla-matched and haploidentical donors with post-transplant cyclophosphamide

Viral infections, particularly cytomegalovirus (CMV), significantly contribute to morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplant (HSCT)1. Post-transplant cyclophosphamide (PTCy)-based platforms for graft-versus-host disease (GVHD) prophylaxis are increasingly used in HSCT, but they may be associated with a higher risk of CMV reactivation2,3, potentially increasing morbidity and non-relapse mortality (NRM). Studies on CMV infections within the context of PTCy have focused on comparisons with calcineurin inhibitors or contrasted HSCT from haploidentical donors (HAPLO) with matched sibling donors (MSD) and/or unrelated donors (MUD)2 –4.

Source: Biology of Blood and Marrow Transplantation - February 5, 2024 Category: Hematology Authors: Pedro Chor ão, Marta Henriques, Marta Villalba, Juan Montoro, Aitana Balaguer-Roselló, Eva María González, María Dolores Gómez, Inés Gómez, Pilar Solves, Marta Santiago, Pedro Asensi, Brais Lamas, Ana Bataller, Pablo Granados, Juan Eiris, David Ma Source Type: research